Data from Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

Autor: Akseli Hemminki, Anna Kanerva, Timo Joensuu, Mauri Kouri, Sirkka-Liisa Holm, Aila Karioja-Kallio, Eerika Karli, Minna Oksanen, Elina Haavisto, Anne Räisänen-Sokolowski, Ari Ristimäki, Laura Ahtiainen, Andreas Helminen, Kilian Guse, Lotta Kangasniemi, Maria Rajecki, Merja Särkioja, Leena Laasonen, Mari Raki, Petri Nokisalmi, Matteo Ugolini, Petteri T. Arstila, Sophie Escutenaire, Iulia Diaconu, Sari Pesonen, Vincenzo Cerullo

Granulocyte macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by recruiting natural killer cells and by induction of tumor-specific cytotoxic T-cells through antigen-presenting cells. Oncolytic tumor cell–killing can produc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d6efec3e0071e39f6ff93a11794299eb
https://doi.org/10.1158/0008-5472.c.6500337

Gold seed fiducials in analysis of linear and rotational displacement of the prostate bed

Autor: Kauko Saarilahti, Elisa Ålander, Jani Keyriläinen, Mauri Kouri, Harri Visapää, Mikko Tenhunen

Publikováno v: Radiotherapy and Oncology. 110:256-260

Background and purpose This study aimed to investigate the magnitude of interfraction prostate bed motion during radiotherapy using both the implanted gold seed fiducials and the soft tissue registration and to define reasonable planning target volum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e60aec0ea3f2522ec6e5d4a39d4613
https://doi.org/10.1016/j.radonc.2013.10.037

[What will determine the first-line treatment of a patient with rectal cancer?]

Autor: Anna, Lepistö, Mauri, Kouri, Ritja, Savolainen, Ari, Ristimäki

Publikováno v: Duodecim; laaketieteellinen aikakauskirja. 132(12)

Treatment of a rectal cancer patient is devised by a multidisciplinary expert team. The first thing to be solved is whether a curative treatment, one slowing the progression of the disease, or a symptomatic treatment is aimed at. The extent of the di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cf10e722238f82ebb2980793bef502ef
https://pubmed.ncbi.nlm.nih.gov/27483636

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial

Autor: Tiina Seppälä, Timo Atula, Sauli Savolainen, Hanna Koivunoro, Kauko Saarilahti, Heikki Minn, Eero Salli, Leena Kankaanranta, Iiro Auterinen, Mauri Kouri, Tom Serén, Petri Kotiluoto, Jouni Uusi-Simola, Juhani Collan, Mika Kortesniemi, Heikki Joensuu, Marko Seppänen, Antti Mäkitie, Hannu Revitzer, Petteri Välimäki

Publikováno v: Kankaanranta, L, Seppälä, T, Koivunoro, H, Saarilahti, K, Atula, T, Collan, J, Salli, E, Kortesniemi, M, Uusi-Simola, J, Välimäki, P, Mäkitie, A, Seppänen, M, Minn, H, Revitzer, H, Kouri, M, Kotiluoto, P, Seren, T, Auterinen, I, Savolainen, S & Joensuu, H 2012, ' Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer : Final analysis of a phase I/II trial ', International Journal of Radiation Oncology Biology Physics, vol. 82, no. 1, pp. e67-e75 . https://doi.org/10.1016/j.ijrobp.2010.09.057

Purpose To investigate the efficacy and safety of boron neutron capture therapy (BNCT) in the treatment of inoperable head-and-neck cancers that recur locally after conventional photon radiation therapy. Methods and Materials In this prospective, sin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c3707e46cc87bdbeed8374da588d79b
https://doi.org/10.1016/j.ijrobp.2010.09.057

A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer

Autor: Greetta Joensuu, Akseli Hemminki, Jorma Isola, Mirja Ruutu, Petri Nokisalmi, Juhani Collan, Timo Joensuu, Mauri Kouri, Patrick A. Kupelian, Sari Pesonen, Chandana A. Reddy

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 78:42-49

To estimate the safety and tolerability of daily administration of 250 mg of gefitinib given concurrently with three-dimensional conformal radiotherapy for patients with nonmetastatic prostate cancer.A total of 42 patients with T2-T3N0M0 tumors were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b8f99c42026a14590803d29bbe32caf
https://doi.org/10.1016/j.ijrobp.2009.07.1731